Konstantin Konstantinov
Director/Board Member presso REPLIGEN CORPORATION
Patrimonio netto: 224 382 $ in data 31/03/2024
Profilo
Konstantin Konstantinov is an Independent Director at Repligen Corp., an Operating Partner at Flagship Pioneering, and the Chief Technology Officer at Ring Therapeutics, Inc. He previously worked as the Vice President at Genzyme Corp., Head of Process Sciences at Bayer Healthcare Pharmaceuticals LLC, and Senior VP of Manufacturing & Process Sciences at Codiak BioSciences, Inc. Konstantinov holds a doctorate degree from Osaka University and undergraduate and graduate degrees from Technical University of Sofia.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
REPLIGEN CORPORATION
0.00% | 18/03/2024 | 1 220 ( 0.00% ) | 224 382 $ | 31/03/2024 |
Posizioni attive di Konstantin Konstantinov
| Società | Posizione | Inizio |
|---|---|---|
| REPLIGEN CORPORATION | Director/Board Member | 26/05/2022 |
Ring Therapeutics, Inc.
 Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 07/06/2023 |
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 07/06/2023 |
Precedenti posizioni note di Konstantin Konstantinov
| Società | Posizione | Fine |
|---|---|---|
| Bayer Healthcare Pharmaceuticals LLC | Corporate Officer/Principal | 01/01/2007 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| CODIAK BIOSCIENCES | Chief Tech/Sci/R&D Officer | - |
Formazione di Konstantin Konstantinov
| Osaka University | Doctorate Degree |
| Technical University of Sofia | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| REPLIGEN CORPORATION | Health Technology |
| Aziende private | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
| Bayer Healthcare Pharmaceuticals LLC | |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Codiak BioSciences, Inc. engages in the development and manufacturing of exosomes. It engages in harnessing exosomes, therapeutic applications, diagnostic applications, and proprietary production. The firm develops engEx Platform, a proprietary and versatile exosome engineering and manufacturing platform, to expand upon the innate properties of exosomes to design novel exosome therapeutics. Codiak BioSciences was founded by Douglas E. William, Raghu Kalluri, and Eric S. Lander in 2015 and is headquartered in Cambridge, MA. | Health Technology |
Ring Therapeutics, Inc.
Ring Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ring Therapeutics, Inc. engages in the development of a gene therapy platform. Its Anellovector platform provides tissue specifities benefitting from the inherent diversity of tropism afforded by the commensal virome. The company was founded in 2000 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Konstantin Konstantinov
